N/A
Completed N=13,340
Evaluating the Efficacy of Pediatric Lipid Screening Alerts
Hypercholesterolemia · Hypercholesterolemia, Familial · Hypercholesteremia in Children · Hyperlipidemia in Children
Source: ClinicalTrials.gov NCT04118348 ↗
Enrolled (actual)
13,340
Serious AEs
—
Results posted
Jan 2022
Primary outcomePrimary: Lipid Panel Order — 156; 454; 236; 494 Participants — p=<.001
Summary
The purpose of the study is to evaluate prospectively the impact of different system alerts on the prescription of lipid panels to pediatric Geisinger patients (9-11 years old), as per the now-universal guidelines. This will help quantify the relative effectiveness of different alerts and combinations of alerts on provider prescribing behavior and patient uptake of screening.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Lipid Panel Order |
156; 454; 236; 494 | <.001 sig |
| PRIMARY Lipid Panel Screening |
47; 98; 70; 120 | <.001 sig |
Eligibility Criteria
Inclusion criteria
- male or female patients between the ages of 9 - 11
- seen within a primary care, cardiology, endocrinology, urgent care (CareWorks), or nutrition clinic at Geisinger
Exclusion criteria
- patients who have completed a lipid screen in the EMR
- patients who were determined to have familial hypercholesterolemia based on prior screening
Data sourced from ClinicalTrials.gov (NCT04118348). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.